Amgen has received approval from the EMEA for Prolia (denosumab) for osteoporosis. The drug’s initial indication will be for women with post-menopausal osteoporosis and men with prostate cancer who, as a result of hormone therapy, are at increased risk of bone fractures. Prolia is administered every six months by injection and is the first in a new class of drugs designed to inhibit proteins that activate bone-destroying cells. The drug is currently under review by the FDA and a decision is ...